Literature DB >> 10629071

Allelic imbalance and mutations of the PTEN gene in ovarian cancer.

M Saito1, A Okamoto, T Kohno, S Takakura, H Shinozaki, S Isonishi, T Yasuhara, T Yoshimura, Y Ohtake, K Ochiai, J Yokota, T Tanaka.   

Abstract

The PTEN/MMAC1/TEP1 tumor-suppressor gene, which maps to chromosome 10q23.3, is mutated and homozygously deleted in a variety of human tumors, including endometrioid-type ovarian tumors. We examined 33 primary ovarian cancers and 3 ovarian borderline tumors for allelic imbalance (AI) of the 10q23.3 region using 5 polymorphic markers, including an insertion/deletion-type polymorphic marker identified in intron 4 of the PTEN gene. AI at one or more loci was detected in 12 of 31 (39%) informative ovarian cancers and none of 3 ovarian borderline tumors. The commonly deleted region was mapped between the D10S215 and D10S541 loci, including the PTEN locus. Moreover, the incidence of AI at the PTEN locus (38%) was the highest among the 5 loci examined. Therefore, we searched for mutations in the entire coding region of the PTEN gene by PCR-SSCP and sequencing analyses in these tumors and 7 ovarian cancer cell lines. Mutations were detected in 3 of the 33 (9%) ovarian cancers: 2 cases with double mutations and 1 case with a mutation on 1 allele accompanied by deletions on both alleles in the poly T tract preceding the splice acceptor site in intron 7. An intragenic deletion was detected in 1 of the 7 (14%) ovarian cancer cell lines. PTEN mutations were detected not only in the endometrioid type but also in the serous and mucinous types of ovarian cancer. However, PTEN was not mutated in the 12 tumors that showed AI of the PTEN locus. Our results suggest that the PTEN gene plays an important role in the development of a subset but diverse histological types of ovarian tumors. However, it is possible that another tumor-suppressor gene in the close vicinity of the PTEN gene is also inactivated by AI of the 10q23.3 region. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629071

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer.

Authors:  Iris N Smith; James M Briggs
Journal:  Proteins       Date:  2016-08-13

3.  A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Authors:  Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2011-03-17       Impact factor: 5.482

4.  Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.

Authors:  K Kurose; X P Zhou; T Araki; S A Cannistra; E R Maher; C Eng
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

Authors:  Chintda Santiskulvong; Gottfried E Konecny; Mirela Fekete; Kuang-Yui Michael Chen; Amer Karam; David Mulholland; Carol Eng; Hong Wu; Min Song; Oliver Dorigo
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

6.  Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.

Authors:  Rong Wu; Tom C Hu; Alnawaz Rehemtulla; Eric R Fearon; Kathleen R Cho
Journal:  Clin Cancer Res       Date:  2011-09-08       Impact factor: 12.531

Review 7.  Genetic factors in ovarian carcinoma.

Authors:  A J Li; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 8.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 9.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

Review 10.  Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

Authors:  Robert J Kurman; Kala Visvanathan; Richard Roden; T C Wu; Ie-Ming Shih
Journal:  Am J Obstet Gynecol       Date:  2008-04       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.